Figure 1. HDAC6 inhibition by Tubastatin A attenuates caspase-3 activation in endothelial cells.

HPAECs and HLMVECs were pre-treated with Tubastatin A (TubA, 3 μM) for 6 h, then challenged with TNF-α (20 ng/ml) for 18 h. Cells were divided into 4 groups: Control (Con), TNF-α alone (TNFα), Tubastatin A alone (TubA), and TNF-α+Tubastatin A (TNFα+TubA). Representative blots and densitometry analysis of cleaved-caspase-3 in HPAECs (A) and HLMVECs (B). *^P < 0.05 versus TNF-α group, n = 3.